PBX3 and acute myeloid leukemia: A small peptide, known as HXR9, that disrupts the interaction between HOX and PBX proteins was found to be effective in killing leukemic cells that were overexpressing HOX/PBX3 genes, which suggests a potential therapeutic strategy for CA-AML patients [93].